NervGen Pharma: Funding, Investors & Team (Sep 2026)
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
NervGen Pharma has raised $60.0M across 1 funding round on record, the most recent an undisclosed round of $60.0M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NervGen Pharma Company Profile and Key Stats
Latest funding round on record: May 2026.
NervGen Pharma Funding Rounds
NervGen Pharma Founders and Leadership Team
Contact details for the NervGen Pharma team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →NervGen Pharma Funding Compared to Other Biotechnology Startups
NervGen Pharma's latest round of $60.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NervGen Pharma in Biotechnology and Vancouver
Companies Similar to NervGen Pharma
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Resverlogix Corporation, a biopharmaceutical company, focuses on the development of novel therapeutics in…
NervGen Pharma Funding FAQs
What does NervGen Pharma do?
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and neurodegenerative diseases. The company's lead compound, NVG-291, has placed ahead for both spinal cord injury and multiple sclerosis. The company plans to initiate a Phase 1 human clinical trial on healthy subjects in early 2020 with an expansion of the trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, the company intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.
How much funding has NervGen Pharma raised?
NervGen Pharma has raised $60.0M across 1 round on record. The most recent is an undisclosed round of $60.0M announced in May 2026.
When did NervGen Pharma last raise funding?
NervGen Pharma's most recent funding round on record is an undisclosed round of $60.0M, announced in May 2026.
Who founded NervGen Pharma?
FundedIQ lists Adam Rogers (Founder) at NervGen Pharma.
Where is NervGen Pharma headquartered?
NervGen Pharma is based in Vancouver, British Columbia, Canada.
How many employees does NervGen Pharma have?
NervGen Pharma is in the 11-50 employee band.
How does NervGen Pharma's funding compare to other Biotechnology startups?
NervGen Pharma's latest round of $60.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's NervGen Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NervGen Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.